Department of Anatomy and Structural Biology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA.
Genomics. 2011 Sep;98(3):164-72. doi: 10.1016/j.ygeno.2011.05.011. Epub 2011 Jun 13.
Microarray profiling in breast cancer patients has identified genes correlated with prognosis whose functions are unknown. The purpose of this study was to develop an in vivo assay for functionally screening regulators of tumor progression using a mouse model. Transductant shRNA cell lines were made in the MDA-MB-231 breast cancer line. A pooled population of 25 transductants was injected into the mammary fat pads and tail veins of mice to evaluate tumor growth, and experimental metastasis. The proportions of transductants were evaluated in the tumor and metastases using barcodes specific to each shRNA transductant. We characterized the homeobox 2 transcription factor as a negative regulator, decreasing tumor growth in MDA-MB-231, T47D, and MTLn3 mammary adenocarcinoma cell lines. Homeobox genes have been correlated with cancer patient prognosis and tumorigenesis. Here we use a novel in vivo shRNA screen to identify a new role for a homeobox gene in human mammary adenocarcinoma.
在乳腺癌患者中进行的微阵列分析确定了与预后相关的基因,但其功能尚不清楚。本研究旨在利用小鼠模型开发一种用于功能性筛选肿瘤进展调节剂的体内测定法。在 MDA-MB-231 乳腺癌系中构建了转导 shRNA 细胞系。将 25 个转导物的混合群体注入小鼠的乳腺脂肪垫和尾静脉中,以评估肿瘤生长和实验性转移。使用针对每个 shRNA 转导物的条形码评估转导物在肿瘤和转移中的比例。我们将同源盒 2 转录因子鉴定为负调节剂,降低 MDA-MB-231、T47D 和 MTLn3 乳腺腺癌细胞系中的肿瘤生长。同源盒基因与癌症患者的预后和肿瘤发生有关。在这里,我们使用新型体内 shRNA 筛选鉴定了同源盒基因在人类乳腺腺癌中的新作用。